Bharat Biotech told to provide phase II data of Covaxin before phase III trial
The SEC also observed that the vaccine was well-tolerated in all dose groups and no serious adverse events have been reported so…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.